Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
RPRX
BUYRoyalty Pharma plc · Healthcare · United States · $33.9B · Avg Vol: $188M/d
COMPANY DESCRIPTION
Royalty Pharma plc is a unique healthcare company focused on acquiring royalty interests in marketed and late-stage biopharmaceutical products. The company's competitive moat lies in its specialized business model, offering capital to biopharmaceutical companies in exchange for future royalty payments, thereby de-risking investments in drug development. This strategy provides diversified exposure to blockbuster therapies without direct R&D costs.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.2B | 2.4B | 2.3B | 2.4B | 2.1% | 2.4B | 2.5B | 2.7B | 6.7% |
| EPS | 0.10 | 2.54 | 1.93 | 1.80 | 162.0% | 1.90 | 1.95 | 2.08 | 7.6% |
| Shares | 443.2M | 446.7M | 446.0M | 428.7M | -3.3% | 443.3M | — | — | — |
| Debt | 7.1B | 6.1B | 7.6B | 9.0B | 7.9% | 9.0B | — | — | — |
| Equity | 5.6B | 6.5B | 6.9B | 6.5B | 4.8% | — | — | — | — |
| Op CF | 2.1B | 3.0B | 2.8B | 2.5B | 5.1% | 2.6B | — | — | — |
| Inv CF | -1.0B | -2.1B | -2.7B | -1.6B | — | — | — | — | — |
| Fin CF | -944.9M | -2.1B | 361.1M | -1.2B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of RPRX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| RPRX | Royalty Pharma plc(you) | $33.9B | 70 | BUY |
| 0HAV.L | Agilent Technologies, Inc. | $36.7B | 60 | HOLD |
| 0JDM.L | IQVIA Holdings Inc. | $33.9B | 57 | HOLD |
| 0J8Z.L | Illumina, Inc. | $18.4B | 69 | BUY |
| REGN.MX | Regeneron Pharmaceuticals, Inc. | $64.9B | 78 | BUY |
| BMRN | BioMarin Pharmaceutical Inc. | $11.5B | 73 | BUY |
| TECH | Bio-Techne Corporation | $11.2B | 68 | BUY |
| 0J9P.L | Incyte Corporation | $20.6B | 88 | STRONG BUY |
| 0KHE.L | Revvity, Inc. | $10.1B | 66 | BUY |
| KRYS | Krystal Biotech, Inc. | $9.9B | 76 | BUY |
Peer medians: ROE -25.4% · P/E 28.8x · Gross margin 50.9%